Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin in Temporomandibular Disorders
NCT05651256Phase 3Completed
- Sponsor
- Universidad de Salamanca
- Start
- Mar 2021
- Primary completion
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botulinum toxin type A in temporomandibular disorders (TMD), sponsored by Universidad de Salamanca. Primary endpoints: Measurement of pain intensity in the masticatory musculature at 6 weeks and Complications in the administration of botulinum toxin at 6 weeks. Started Mar 2021; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
temporomandibular disorders (TMD)
Beyond the preview
Go deeper on NCT05651256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05651256.